HHS Project NextGen to study novel COVID-19 vaccines, technologies
The Department of Health and Human Services’ Administration for Strategic Preparedness and Response recently awarded over $500 million to prepare for clinical trial three COVID-19 vaccine candidates that target better or longer-lasting immune response; increase central laboratory capacity for sample testing; and investigate better ways to develop monoclonal antibodies and evaluate and administer vaccines.
“By investing in next-generation vaccines and treatments, we can improve our ability to respond to new variants, reduce transmission, stop infections, and save lives,” said HHS Secretary Xavier Becerra.
Related News Articles
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…